OTLK vs REGN
OTLK: Outlook Therapeutics is the developer of LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration. REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
Side-by-side fundamentals
| Metric | OTLK | REGN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $0.52 | $807.48 | |
| Market cap | $127M | $83.1B | |
| P/E as of 2026-10-20 | n/a | 19.98 | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | n/a | 7.22 | |
| Net margin FY2025, SEC XBRL | -4416.2% | +31.4% | REGN higher |
| Gross margin FY2025, SEC XBRL | +4.0% | n/a | |
| Operating margin FY2025, SEC XBRL | -4744.3% | +24.9% | REGN higher |
| ROE FY2025, SEC XBRL | n/a | +14.4% | |
| ROA FY2025, SEC XBRL | -335.9% | +11.1% | REGN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.06 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +1.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.6% | |
| Dividend yield as of 2026-09-02 | n/a | +0.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 1.03 | 0.60 | |
| 1-year return as of 2026-10-20 close | -64.9% | +40.0% | REGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.